ArticleFrontiers in oncology2026
Development and validation of multidimensional nomograms for predicting prostate cancer risk: a retrospective study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: PSA screening has limited specificity in the 10-20 ng/mL range, making biopsy decisions difficult. Metabolic disorders and inflammation may improve risk prediction. We aimed to develop a model integrating multidimensional indicators to predict prostate cancer and high-grade disease in men with tPSA >10 ng/mL. Methods: This retrospective study included 461 men who underwent prostate biopsy (tPSA >10 ng/mL). Patients were randomly split into training (70%) and validation (30%) sets. Two logistic regression models were built: Model 1 for benign vs. malignant; Model 2 (in malignant cases) for high-grade (ISUP ≥3) vs. low-grade. Variables with VIF>5 were excluded. Backward stepwise (AIC) and univariate Result: Among 461 patients, 252 (54.7%) had prostate cancer, and 139 (55.2% of malignant cases) had high-grade disease. Malignant patients were older, had higher BMI, TyG index, NLR, and tPSA, and lower fPSA% (all Conclusion: Two nomograms using routine clinical and laboratory variables may assist in risk stratification for prostate cancer and high-grade disease in men with tPSA >10 ng/mL, outperforming fPSA% alone. These tools can help reduce unnecessary biopsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.